Trial · NCT00806585

Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)

NCT00806585, Phase 2, Terminated, Merck Sharp & Dohme LLC; results first posted 2013-12-11

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007). Trials, record NCT00806585. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00806585

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)
NCT number: NCT00806585
Status: Terminated
Phases: Phase 2
Enrollment: 620 participants, actual
Lead sponsor: Merck Sharp & Dohme LLC
Conditions: Type 2 Diabetes Mellitus, Hypertension
Interventions: MK-0736, Comparator: Placebo, Comparator: HCTZ
First posted: 2008-12-11
Last updated: 2015-09-21
Results first posted: 2013-12-11

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change From Baseline in Sitting Diastolic Blood Pressure (SiDBP) at Week 12	Baseline and Week 12	Participant remained in the sitting position for at least 5 minutes before any blood pressure readings were recorded. Systolic and diastolic blood pressures were determined by taking 6 replicate measurements obtained 1 to 2 minutes apart. First reading was discarded and the average of the last 5 measurement was recorded.
Primary	Change From Baseline in Sitting Systolic Blood Pressure (SiSBP) at Week 12	Baseline and Week 12	Participant remained in the sitting position for at least 5 minutes before any blood pressure readings were recorded. Systolic and diastolic blood pressures were determined by taking 6 replicate measurements obtained 1 to 2 minutes apart. First reading was discarded and the average the last 5 measurement was recorded.
Secondary	Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12	Baseline and Week 12	LDL-C calculated by the method of Friedewald equation at baseline and after 12 weeks of study drug administration
Secondary	Change From Baseline in Body Weight at Week 24	Baseline and Week 24	Fasting weight was assessed at baseline and after 24 weeks of study drug administration and was measured after voiding, with shoes and socks off, wearing clinic gown to reduce variability and maintain consistency. Same standardized digital scale was used throughout the study.
Secondary	Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24	Baseline and Week 24	HbA1c reported as a % and was measured at baseline and after 24 weeks of study drug administration

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change From Baseline in Sitting Diastolic Blood Pressure (SiDBP) at Week 12	Baseline and Week 12	Full Analysis Set (FAS) Population defined as all participants who received at least 1 dose of study drug and had endpoint data (both baseline and post-randomization)	mmHg	LEAST_SQUARES_MEAN
PRIMARY	Change From Baseline in Sitting Systolic Blood Pressure (SiSBP) at Week 12	Baseline and Week 12	Full Analysis Set (FAS) Population defined as all participants who received at least 1 dose of study drug and had endpoint data (both baseline and post-randomization)	mmHg	LEAST_SQUARES_MEAN
SECONDARY	Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12	Baseline and Week 12	Full Analysis Set (FAS) Population defined as all participants who received at least 1 dose of study drug and had endpoint data (both baseline and post-randomization)	Percentage Change	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Body Weight at Week 24	Baseline and Week 24	Full Analysis Set (FAS) Population defined as all participants who received at least 1 dose of study drug and had endpoint data (both baseline and post-randomization)	kg	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24	Baseline and Week 24	Full Analysis Set (FAS) Population defined as all participants who received at least 1 dose of study drug and did not lack of any endpoint data (both baseline and post-randomization)	Percentage Change	LEAST_SQUARES_MEAN

Source ClinicalTrials.gov

Results by group25

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change From Baseline in Sitting Diastolic Blood Pressure (SiDBP) at Week 12	MK-0736 0.5 mg	-5.8	Standard Error 0.7	mmHg
Change From Baseline in Sitting Diastolic Blood Pressure (SiDBP) at Week 12	MK-0736 2.0 mg	-5.7	Standard Error 0.7	mmHg
Change From Baseline in Sitting Diastolic Blood Pressure (SiDBP) at Week 12	MK-0736 8.0 mg	-6.7	Standard Error 0.7	mmHg
Change From Baseline in Sitting Diastolic Blood Pressure (SiDBP) at Week 12	HCTZ 12.5 mg → MK-0736 8.0 mg	-7.7	Standard Error 1.0	mmHg
Change From Baseline in Sitting Diastolic Blood Pressure (SiDBP) at Week 12	Placebo	-5.6	Standard Error 0.7	mmHg
Change From Baseline in Sitting Systolic Blood Pressure (SiSBP) at Week 12	MK-0736 0.5 mg	-5.7	Standard Error 1.1	mmHg
Change From Baseline in Sitting Systolic Blood Pressure (SiSBP) at Week 12	MK-0736 2.0 mg	-7.2	Standard Error 1.1	mmHg
Change From Baseline in Sitting Systolic Blood Pressure (SiSBP) at Week 12	MK-0736 8.0 mg	-6.3	Standard Error 1.1	mmHg
Change From Baseline in Sitting Systolic Blood Pressure (SiSBP) at Week 12	HCTZ 12.5 mg → MK-0736 8.0 mg	-12.4	Standard Error 1.5	mmHg
Change From Baseline in Sitting Systolic Blood Pressure (SiSBP) at Week 12	Placebo	-5.4	Standard Error 1.2	mmHg

1 to 10 of 25Source ClinicalTrials.gov

See all 25 results by group

Participant flow15

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	MK-0736 0.5 mg	137
Overall Study	STARTED	MK-0736 2.0 mg	134
Overall Study	STARTED	MK-0736 8.0 mg	141
Overall Study	STARTED	HCTZ 12.5 mg → MK-0736 8.0 mg	71
Overall Study	STARTED	Placebo	137
Overall Study	COMPLETED	MK-0736 0.5 mg	105
Overall Study	COMPLETED	MK-0736 2.0 mg	103
Overall Study	COMPLETED	MK-0736 8.0 mg	109
Overall Study	COMPLETED	HCTZ 12.5 mg → MK-0736 8.0 mg	56
Overall Study	COMPLETED	Placebo	106

1 to 10 of 15Source ClinicalTrials.gov

See all 15 participant flow

Adverse events170

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Oedema peripheral	General disorders	MK-0736 0.5 mg	1	137	1
other	Oedema peripheral	General disorders	MK-0736 2.0 mg	2	134	2
other	Oedema peripheral	General disorders	MK-0736 8.0 mg	8	141	10
other	Oedema peripheral	General disorders	HCTZ 12.5 mg → MK-0736 8.0 mg	2	71	2
other	Oedema peripheral	General disorders	Placebo	2	137	2
other	Nasopharyngitis	Infections and infestations	MK-0736 0.5 mg	2	137	2
other	Nasopharyngitis	Infections and infestations	MK-0736 2.0 mg	8	134	9
other	Nasopharyngitis	Infections and infestations	MK-0736 8.0 mg	3	141	4
other	Nasopharyngitis	Infections and infestations	HCTZ 12.5 mg → MK-0736 8.0 mg	2	71	2
other	Nasopharyngitis	Infections and infestations	Placebo	5	137	5

1 to 10 of 170Source ClinicalTrials.gov

See all 170 adverse events

Adverse event totals15

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	MK-0736 0.5 mg
Total, all-cause mortality	MK-0736 2.0 mg
Total, all-cause mortality	MK-0736 8.0 mg
Total, all-cause mortality	HCTZ 12.5 mg → MK-0736 8.0 mg
Total, all-cause mortality	Placebo
Total, other adverse events	MK-0736 0.5 mg	46	137
Total, other adverse events	MK-0736 2.0 mg	54	134
Total, other adverse events	MK-0736 8.0 mg	54	141
Total, other adverse events	HCTZ 12.5 mg → MK-0736 8.0 mg	25	71
Total, other adverse events	Placebo	43	137

1 to 10 of 15Source ClinicalTrials.gov

See all 15 adverse event totals

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00806585

GET https://conductscience.org/api/trials/v1/NCT00806585/results?page=2

API reference For AI assistants